CURRENT OPEN TRIALS

Protocol

WCRF 452

​

​

Protocol

WCRF 455

​

​

Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)

​

​

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

RECENTLY COMPLETED TRIALS

Protocol

WCRF 453

​

​

Protocol

WCRF 454

​

​

Protocol

WCRF 465

​

​

​

​

Protocol WCRF 451

​

​

Protocol

GOA-NVM1

​

​

Protocol

GOG-0261

​

​

Protocol

GOG-186

​

​

Protocol 

GOG-0241

​

​

​

Protocol

GOG-0258

​

​

Protocol

08-PIR-04

​

​

Protocol 

GOA-TCOV

​

​

Protocol

3144A2-3004-WW

​

​

Protocol 

XL147-201

​

​

Protocol

GOAWP3C

​

​

Protocol

SHH4489g  -01/2011

​

​

Protocol DOXILOVC2007 -01/2011

​

​

Protocol EC-FV-04 -10/2010

​

​

Protocol MORAb-003-004 -8/2010

​

​

Protocol M10-747  -9/1/2010

​

​

Protocol 20060342   -2010

​

​

Protocol SPO-0010  -2010

​

​

Protocol AVF4095g  -2010

​

​

Protocol AVF4121s

​

​

​

Protocol AVF3206s

​

​

​

Protocol Perifosine 207

​

​

Protocol Perifosine 211

​

​

Protocol PXD101-CLN-8

​

​

Protocol EC-FV-02

​

​

A phase II trial evaluating the efficacy of Akynzeo in the management of chemotherapy induced nausea and vomiting in patients treated for advanced stage ovarian carcinoma

​

A randomized , open-label, multicenter, phase 3 study to evaluate the efficacy and safety of AVELUMAB (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer

​

​A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer and a response or stable disease to platinum therapy

An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma

​

A phase IV, randomized, double-blinded, multi-center study comparing the efficacy of Fosaprepitant with standard pre-medications to aprepitant with standard pre-medications for chemotherapy induced nausea and vomiting in patients treated for gynecological cancer

​

A randomized phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in chemotherapy-naive patients with newly diagnosed stage I-V persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus, fallopian tube, peritoneum or ovary

​

A randomized Phase IIB evaluation of weekly Paclitaxel (NSC #673089) plus Pazopanib (NSC #737754) (IND #75648) versus weekly Paclitaxel plus placebo in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

​

A GCIG intergroup multicenter phase III trial of open label Carboplatin and Paclitaxel +/- NCI-supplied agent: Bevacizumab (NSC #704865, IND #113912) compared with Oxaliplatin and Capecitabine +/- Bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian or fallopian tube cancer (MEOC)

​

A randomized phase III trial of Cisplatin and tumor volume directed irradiation followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for optimally debulked, advanced endometrial carcinoma

​

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer

​

A Phase I/II, Open-Label, Non-Randomized, Pilot Study of weekly Paclitaxel, every four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed with Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

​

A Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early HER-2/neu Overexpressed/ Amplified Breast Cancer

​

​

A Phase 2 Study of XL147 in subjects with advanced or recurrent endometrial carcinoma

​

​

A Phase II, open-label, non-randomized, multi-center study of weekly Paclitaxel and every 3 week Carboplatin for treatment of primary epithelial ovarian, fallopian tube, peritoneal or malignant peritoneal mesothelioma

​

A phase II multicenter, randomized, double blind, placebo controlled trial evaluating the efficacy and safety of GDC-0449 as maintenance therapy in patients with ovarian cancer in a second or third complete

​

​

A Phase II Single Arm Study of Carboplatin and DOXIL® plus Bevacizumab in Subjects with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

​

​

A randomized phase II trial comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in combination versus PLD alone in subjects with paltinum resistant ovarian cancer

​

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse

​

A Phase 2 Randomized clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serious Ovarian Cancer

​

A randomized, double-blind, placebo controlled phase 2 trial of paclitaxel in combination with AMG 386 in subjects with advanced recurrent epithelial ovarian or primary peritoneal cancer

​

​

A phase 2 open-label, multicenter study of SNS‑595 injection in patients with platinum-resistant ovarian cancer

​

​

A phase II, multicenter, randomized, blinded, placebo-controlled trial of Carboplatin and Gemcitabine plus Bevacizumab in patients with platinum‑sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma

​

A phase II, open-label, non-randomized, pilot study of weekly paclitaxel and every four-week carboplatin with bevacizumab given every two weeks for patients newly diagnosed with stage III/IV epithelial ovarian, fallopian tube or peritoneal cancer

​

A Phase II, open-label, non-randomized, multi-center pilot study of Intravenous Taxol, Carboplatin, and Bevacizumab (Avastin) given every 21 days in patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube, or peritoneal cancer

​

A Phase IIA trial of two schedules of Perifosine in patients for whom no standard therapy exists

​

​

A randomized placebo controlled study of Perifosine in combination with single agent chemotherapy for second-line metastatic cancer patients

​

​

A phase I safety, pharmacodynamic, and pharmacokinetic study of intravenously administered PXD101 plus Carboplatin or Paclitaxel or both in patients with advanced solid tumours

​

A phase II study of EC 145 in patients with advanced ovarian and endometrial cancers

​